|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM131136941 |
| 003 |
DE-627 |
| 005 |
20250204104647.0 |
| 007 |
tu |
| 008 |
231222s1956 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0437.xml
|
| 035 |
|
|
|a (DE-627)NLM131136941
|
| 035 |
|
|
|a (NLM)13366519
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a MICHAILE, K I
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The use of a sustained-release d-amphetamine-amobarbital preparation in the treatment of obesity
|
| 264 |
|
1 |
|c 1956
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.05.2002
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a AMOBARBITAL/therapeutic use
|
| 650 |
|
4 |
|a AMPHETAMINE/therapeutic use
|
| 650 |
|
4 |
|a OBESITY/therapy
|
| 650 |
|
7 |
|a Amphetamines
|2 NLM
|
| 650 |
|
7 |
|a Delayed-Action Preparations
|2 NLM
|
| 650 |
|
7 |
|a Amphetamine
|2 NLM
|
| 650 |
|
7 |
|a CK833KGX7E
|2 NLM
|
| 650 |
|
7 |
|a Amobarbital
|2 NLM
|
| 650 |
|
7 |
|a GWH6IJ239E
|2 NLM
|
| 650 |
|
7 |
|a Dextroamphetamine
|2 NLM
|
| 650 |
|
7 |
|a TZ47U051FI
|2 NLM
|
| 700 |
1 |
|
|a SHAPIRO, R P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t International record of medicine and general practice clinics
|d 1952
|g 169(1956), 10 vom: 16. Okt., Seite 638-41
|w (DE-627)NLM098172042
|x 0097-1650
|7 nnns
|
| 773 |
1 |
8 |
|g volume:169
|g year:1956
|g number:10
|g day:16
|g month:10
|g pages:638-41
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 169
|j 1956
|e 10
|b 16
|c 10
|h 638-41
|